VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q59700138 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010722.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q59700138‏
024 ‎‡a 0000-0003-4440-726X‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q59700138‏
100 0 ‎‡a Charles P Hart‏ ‎‡9 es‏ ‎‡9 ast‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a চার্লস পি হার্ট‏ ‎‡9 bn‏
400 0 ‎‡a Charles P Hart‏ ‎‡c researcher ORCID ID = 0000-0003-4440-726X‏ ‎‡9 en‏
400 0 ‎‡a Charles P Hart‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's 14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment‏
670 ‎‡a Author's A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.‏
670 ‎‡a Author's Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.‏
670 ‎‡a Author's ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation.‏
670 ‎‡a Author's Cognate homeo-box loci mapped on homologous human and mouse chromosomes‏
670 ‎‡a Author's Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models‏
670 ‎‡a Author's Comparison of hypoxia-activated prodrug evofosfamide‏
670 ‎‡a Author's Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.‏
670 ‎‡a Author's DD-02PHARMACODYNAMIC BIOMARKER ASSESSMENTS IN A PHASE I/II TRIAL OF THE HYPOXIA-ACTIVATED PRODRUG TH-302 AND BEVACIZUMAB IN BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA‏
670 ‎‡a Author's Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer‏
670 ‎‡a Author's Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition‏
670 ‎‡a Author's Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer‏
670 ‎‡a Author's Genetic linkage analysis of the murine developmental mutant velvet coat (Ve) and the distal chromosome 15 developmental genes Hox-3.1, Rar-g, Wnt-1, and Krt-2‏
670 ‎‡a Author's Genetic Recombination as a Reporter for Screening Steroid Receptor Agonists and Antagonists‏
670 ‎‡a Author's Homeo box genes in murine development.‏
670 ‎‡a Author's Homeotic transformation of the occipital bones of the skull by ectopic expression of a homeobox gene‏
670 ‎‡a Author's Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas‏
670 ‎‡a Author's Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models‏
670 ‎‡a Author's Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models.‏
670 ‎‡a Author's Mammalian homeo box genes‏
670 ‎‡a Author's Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.‏
670 ‎‡a Author's Molecular cloning and chromosome assignment of murine N-ras‏
670 ‎‡a Author's Molecular cloning and chromosome mapping of a mouse DNA sequence homologous to homeotic genes of Drosophila.‏
670 ‎‡a Author's MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts‏
670 ‎‡a Author's Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy‏
670 ‎‡a Author's Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.‏
670 ‎‡a Author's Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.‏
670 ‎‡a Author's Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.‏
670 ‎‡a Author's Reproducible subcellular alterations in hepatocytes resulting from ultrasound‏
670 ‎‡a Author's Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.‏
670 ‎‡a Author's Sequence analysis of the murine Hox-2.2, -2.3, and -2.4 homeo boxes: evolutionary and structural comparisons.‏
670 ‎‡a Author's Spatial restriction in expression of a mouse homoeo box locus within the central nervous system.‏
670 ‎‡a Author's TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.‏
670 ‎‡a Author's TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.‏
909 ‎‡a (orcid) 000000034440726x‏ ‎‡9 1‏
919 ‎‡a comparisonofhypoxiaactivatedprodrugevofosfamideth302andifosfamideinpreclinicalnonsmallcelllungcancermodels‏ ‎‡A Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.‏ ‎‡9 1‏
919 ‎‡a arc111inhibitshypoxiamediatedhypoxiainduciblefactor1alphaaccumulation‏ ‎‡A ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation.‏ ‎‡9 1‏
919 ‎‡a novelclassoftubulininhibitorsthatexhibitpotentantiproliferationandinvitrovesseldisruptingactivity‏ ‎‡A A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.‏ ‎‡9 1‏
919 ‎‡a 14aminocamptothecinstheirsynthesispreclinicalactivityandpotentialuseforcancertreatment‏ ‎‡A 14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment‏ ‎‡9 1‏
919 ‎‡a activityofthehypoxiaactivatedprodrugth302inpreclinicalhumanacutemyeloidleukemiamodels‏ ‎‡A Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.‏ ‎‡9 1‏
919 ‎‡a combinationtreatmentwithhypoxiaactivatedprodrugevofosfamideth302andmtorinhibitorsresultsinenhancedantitumorefficacyinpreclinicalrenalcellcarcinomamodels‏ ‎‡A Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models‏ ‎‡9 1‏
919 ‎‡a comparisonofhypoxiaactivatedprodrugevofosfamide‏ ‎‡A Comparison of hypoxia-activated prodrug evofosfamide‏ ‎‡9 1‏
919 ‎‡a cognatehomeoboxlocimappedonhomologoushumanandmousechromosomes‏ ‎‡A Cognate homeo-box loci mapped on homologous human and mouse chromosomes‏ ‎‡9 1‏
919 ‎‡a efficacyandsafetyofthehypoxiaactivatedprodrugth302incombinationwithgemcitabineandnabpaclitaxelinhumantumorxenograftmodelsofpancreaticcancer‏ ‎‡A Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer‏ ‎‡9 1‏
919 ‎‡a dd02pharmacodynamicbiomarkerassessmentsinaphase12trialofthehypoxiaactivatedprodrugth302andbevacizumabinbevacizumabrefractoryrecurrentglioblastoma‏ ‎‡A DD-02PHARMACODYNAMIC BIOMARKER ASSESSMENTS IN A PHASE I/II TRIAL OF THE HYPOXIA-ACTIVATED PRODRUG TH-302 AND BEVACIZUMAB IN BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA‏ ‎‡9 1‏
919 ‎‡a enhancementofhypoxiaactivatedprodrugth302antitumoractivitybychk1inhibition‏ ‎‡A Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition‏ ‎‡9 1‏
919 ‎‡a potentandhighlyselectivehypoxiaactivatedachiralphosphoramidatemustardsasanticancerdrugs‏ ‎‡A Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.‏ ‎‡9 1‏
919 ‎‡a spatialrestrictioninexpressionofamousehomoeoboxlocuswithinthecentralnervoussystem‏ ‎‡A Spatial restriction in expression of a mouse homoeo box locus within the central nervous system.‏ ‎‡9 1‏
919 ‎‡a selectivetumorhypoxiatargetingbyhypoxiaactivatedprodrugth302inhibitstumorgrowthinpreclinicalmodelsofcancer‏ ‎‡A Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.‏ ‎‡9 1‏
919 ‎‡a reproduciblesubcellularalterationsinhepatocytesresultingfromultrasound‏ ‎‡A Reproducible subcellular alterations in hepatocytes resulting from ultrasound‏ ‎‡9 1‏
919 ‎‡a pyruvateinducestransienttumorhypoxiabyenhancingmitochondrialoxygenconsumptionandpotentiatestheantitumoreffectofahypoxiaactivatedprodrugth302‏ ‎‡A Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.‏ ‎‡9 1‏
919 ‎‡a th302ahypoxiaactivatedprodrugwithbroadinvivopreclinicalcombinationtherapyefficacyoptimizationofdosingregimensandschedules‏ ‎‡A TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.‏ ‎‡9 1‏
919 ‎‡a multimodaltargetingoftumorvasculatureandcancerstemlikecellsinsarcomaswithvegfainhibitionhif1αinhibitionandhypoxiaactivatedchemotherapy‏ ‎‡A Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy‏ ‎‡9 1‏
919 ‎‡a mrimagingbiomarkerstomonitorearlyresponsetohypoxiaactivatedprodrugth302inpancreaticcancerxenografts‏ ‎‡A MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts‏ ‎‡9 1‏
919 ‎‡a molecularcloningandchromosomemappingofamousednasequencehomologoustohomeoticgenesofdrosophila‏ ‎‡A Molecular cloning and chromosome mapping of a mouse DNA sequence homologous to homeotic genes of Drosophila.‏ ‎‡9 1‏
919 ‎‡a molecularcloningandchromosomeassignmentofmurinenras‏ ‎‡A Molecular cloning and chromosome assignment of murine N-ras‏ ‎‡9 1‏
919 ‎‡a molecularandcellularpharmacologyofthehypoxiaactivatedprodrugth302‏ ‎‡A Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.‏ ‎‡9 1‏
919 ‎‡a mammalianhomeoboxgenes‏ ‎‡A Mammalian homeo box genes‏ ‎‡9 1‏
919 ‎‡a hypoxiaimagingwithpetcorrelateswithantitumoractivityofthehypoxiaactivatedprodrugevofosfamideth302inrodentgliomamodels‏ ‎‡A Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models.‏ ‎‡9 1‏
919 ‎‡a th302incombinationwithradiotherapyenhancesthetherapeuticoutcomeandisassociatedwithpretreatmenthx4hypoxiapetimaging‏ ‎‡A TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.‏ ‎‡9 1‏
919 ‎‡a hypoxiaactivatedprodrugth302targetshypoxicbonemarrownichesinpreclinicalleukemiamodels‏ ‎‡A Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models‏ ‎‡9 1‏
919 ‎‡a sequenceanalysisofthemurinehox2223and24homeoboxesevolutionaryandstructuralcomparisons‏ ‎‡A Sequence analysis of the murine Hox-2.2, -2.3, and -2.4 homeo boxes: evolutionary and structural comparisons.‏ ‎‡9 1‏
919 ‎‡a hypoxiaactivatedchemotherapeuticth302enhancestheeffectsofvegfainhibitionandradiationonsarcomas‏ ‎‡A Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas‏ ‎‡9 1‏
919 ‎‡a homeotictransformationoftheoccipitalbonesoftheskullbyectopicexpressionofahomeoboxgene‏ ‎‡A Homeotic transformation of the occipital bones of the skull by ectopic expression of a homeobox gene‏ ‎‡9 1‏
919 ‎‡a homeoboxgenesinmurinedevelopment‏ ‎‡A Homeo box genes in murine development.‏ ‎‡9 1‏
919 ‎‡a geneticrecombinationasareporterforscreeningsteroidreceptoragonistsandantagonists‏ ‎‡A Genetic Recombination as a Reporter for Screening Steroid Receptor Agonists and Antagonists‏ ‎‡9 1‏
919 ‎‡a preclinicalbenefitofhypoxiaactivatedintraarterialtherapywithevofosfamideinlivercancer‏ ‎‡A Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.‏ ‎‡9 1‏
919 ‎‡a geneticlinkageanalysisofthemurinedevelopmentalmutantvelvetcoatveandthedistalchromosome15developmentalgeneshox31rargwnt1andkrt2‏ ‎‡A Genetic linkage analysis of the murine developmental mutant velvet coat (Ve) and the distal chromosome 15 developmental genes Hox-3.1, Rar-g, Wnt-1, and Krt-2‏ ‎‡9 1‏
919 ‎‡a evaluationofthestealphenomenonontheefficacyofhypoxiaactivatedprodrugth302inpancreaticcancer‏ ‎‡A Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 NUKAT|n 2018282538‏
996 ‎‡2 BIBSYS|98038428‏
996 ‎‡2 BNF|14607235‏
996 ‎‡2 J9U|987007391104205171‏
996 ‎‡2 SUDOC|236342878‏
996 ‎‡2 JPG|500069900‏
996 ‎‡2 DNB|130391824‏
996 ‎‡2 LC|no2001009380‏
996 ‎‡2 NUKAT|n 2020162653‏
996 ‎‡2 JPG|500060291‏
996 ‎‡2 DNB|1055463372‏
996 ‎‡2 CAOONL|ncf10284081‏
996 ‎‡2 JPG|500490070‏
996 ‎‡2 KRNLK|KAC200905049‏
996 ‎‡2 ISNI|0000000037040998‏
996 ‎‡2 SUDOC|234809183‏
996 ‎‡2 LC|n 2021042022‏
996 ‎‡2 J9U|987007262306305171‏
996 ‎‡2 W2Z|1523345894486‏
996 ‎‡2 LC|no2001005494‏
996 ‎‡2 BNF|16664036‏
996 ‎‡2 CAOONL|ncf11441809‏
996 ‎‡2 ISNI|0000000389501110‏
996 ‎‡2 BIBSYS|90153194‏
996 ‎‡2 DNB|134398726‏
996 ‎‡2 SUDOC|17865339X‏
996 ‎‡2 ISNI|000000005446475X‏
996 ‎‡2 NYNYRILM|171182‏
996 ‎‡2 BIBSYS|28607‏
996 ‎‡2 NYNYRILM|171184‏
996 ‎‡2 LC|n 84077704‏
996 ‎‡2 NUKAT|n 2016172264‏
996 ‎‡2 LC|n 2018041353‏
996 ‎‡2 NTA|073563676‏
996 ‎‡2 BIBSYS|13011214‏
996 ‎‡2 BIBSYS|7057787‏
996 ‎‡2 RERO|A013277806‏
996 ‎‡2 NII|DA16938262‏
996 ‎‡2 ISNI|0000000033639581‏
996 ‎‡2 BNF|12442202‏
996 ‎‡2 NTA|069648190‏
996 ‎‡2 LC|n 2012188353‏
996 ‎‡2 J9U|987007335062205171‏
996 ‎‡2 LC|n 85062321‏
996 ‎‡2 NDL|01051586‏
996 ‎‡2 DNB|142982687‏
996 ‎‡2 RERO|A003349996‏
996 ‎‡2 LC|no 97070162‏
996 ‎‡2 ISNI|000000003795743X‏
996 ‎‡2 LC|no2007018481‏
996 ‎‡2 SUDOC|178929859‏
996 ‎‡2 NYNYRILM|316784‏
996 ‎‡2 DNB|127815597‏
996 ‎‡2 DNB|127815619‏
996 ‎‡2 BNC|981058515631706706‏
996 ‎‡2 NII|DA00815605‏
996 ‎‡2 ISNI|0000000040201465‏
996 ‎‡2 LC|nb2003082981‏
996 ‎‡2 RERO|A003349992‏
996 ‎‡2 RERO|A003349994‏
996 ‎‡2 ISNI|0000000039660285‏
996 ‎‡2 NII|DA06527578‏
996 ‎‡2 ISNI|0000000035909039‏
996 ‎‡2 DBC|87097969505678‏
996 ‎‡2 RERO|A003349999‏
996 ‎‡2 LC|n 86053478‏
996 ‎‡2 ISNI|0000000395397874‏
996 ‎‡2 NTA|070386749‏
996 ‎‡2 PLWABN|9810636030505606‏
996 ‎‡2 LC|n 88211473‏
996 ‎‡2 NDL|00522427‏
996 ‎‡2 LC|n 82091004‏
996 ‎‡2 LC|nr 95014654‏
996 ‎‡2 BIBSYS|90170504‏
996 ‎‡2 LC|no2018093433‏
996 ‎‡2 LNB|LNC10-000013217‏
996 ‎‡2 LC|n 2005020200‏
996 ‎‡2 NII|DA04942091‏
996 ‎‡2 ISNI|0000000036441984‏
996 ‎‡2 ISNI|0000000387135276‏
996 ‎‡2 LC|nr2003021726‏
996 ‎‡2 ISNI|0000000074616466‏
996 ‎‡2 DNB|172126843‏
996 ‎‡2 J9U|987007390669405171‏
996 ‎‡2 ISNI|0000000384852050‏
996 ‎‡2 BNF|14185656‏
996 ‎‡2 ISNI|0000000050018330‏
996 ‎‡2 ISNI|0000000396630930‏
996 ‎‡2 ISNI|0000000054173362‏
996 ‎‡2 DNB|1014041880‏
996 ‎‡2 NTA|238066177‏
996 ‎‡2 JPG|500107331‏
996 ‎‡2 BLBNB|001115529‏
996 ‎‡2 NDL|001254434‏
996 ‎‡2 ISNI|0000000063519425‏
996 ‎‡2 LNB|LNC10-000297693‏
996 ‎‡2 ISNI|0000000080255193‏
996 ‎‡2 DNB|1055371761‏
996 ‎‡2 CAOONL|ncf10515953‏
996 ‎‡2 LC|no2003027013‏
996 ‎‡2 LC|n 83041836‏
996 ‎‡2 J9U|987007417773905171‏
996 ‎‡2 J9U|987007279943005171‏
996 ‎‡2 NTA|068918208‏
996 ‎‡2 NTA|07234704X‏
996 ‎‡2 LC|nb2010014871‏
996 ‎‡2 W2Z|98038428‏
996 ‎‡2 ISNI|0000000499383792‏
996 ‎‡2 LC|n 2012074670‏
996 ‎‡2 ISNI|0000000050581246‏
996 ‎‡2 BIBSYS|8015008‏
996 ‎‡2 LC|no2008092747‏
996 ‎‡2 PLWABN|9811343757905606‏
996 ‎‡2 NTA|380209004‏
996 ‎‡2 ISNI|0000000031505280‏
996 ‎‡2 J9U|987007277059805171‏
996 ‎‡2 LC|no2009074657‏
996 ‎‡2 RERO|A014055181‏
996 ‎‡2 ISNI|0000000049081260‏
996 ‎‡2 RERO|A012709534‏
996 ‎‡2 ISNI|0000000023661013‏
996 ‎‡2 ISNI|000000011020630X‏
996 ‎‡2 LC|no 00072026‏
996 ‎‡2 NTA|432136649‏
996 ‎‡2 DNB|117498572‏
996 ‎‡2 ISNI|0000000110511283‏
996 ‎‡2 ISNI|0000000140139494‏
996 ‎‡2 RERO|A005987391‏
996 ‎‡2 NII|DA18817214‏
996 ‎‡2 LC|no2011048368‏
996 ‎‡2 DNB|1012789284‏
996 ‎‡2 DBC|87097990934716‏
996 ‎‡2 ISNI|0000000123577011‏
996 ‎‡2 LC|no2003072254‏
996 ‎‡2 CAOONL|ncf10863026‏
996 ‎‡2 ISNI|0000000490015395‏
996 ‎‡2 ISNI|0000000360970976‏
996 ‎‡2 LC|no2007064349‏
996 ‎‡2 NTA|141687134‏
996 ‎‡2 NTA|277355184‏
996 ‎‡2 LC|n 87870833‏
996 ‎‡2 LC|n 50050520‏
996 ‎‡2 ISNI|0000000074073318‏
996 ‎‡2 NSK|000172733‏
996 ‎‡2 SUDOC|087277964‏
996 ‎‡2 LC|n 2007068177‏
996 ‎‡2 LC|n 2008009036‏
996 ‎‡2 DNB|1057178098‏
996 ‎‡2 DNB|1328172465‏
996 ‎‡2 SUDOC|070694842‏
996 ‎‡2 SUDOC|115379754‏
996 ‎‡2 LC|no2013055763‏
996 ‎‡2 SUDOC|129045233‏
996 ‎‡2 BIBSYS|90259241‏
996 ‎‡2 ISNI|0000000434850767‏
996 ‎‡2 DBC|87097939256053‏
996 ‎‡2 DNB|1122068786‏
996 ‎‡2 J9U|987007431353005171‏
996 ‎‡2 SUDOC|153669853‏
996 ‎‡2 ISNI|0000000047555880‏
996 ‎‡2 BIBSYS|1523345894486‏
996 ‎‡2 BAV|495_77879‏
996 ‎‡2 NII|DA08085470‏
996 ‎‡2 KRNLK|KAC200702446‏
996 ‎‡2 LC|no2016116478‏
996 ‎‡2 NLA|000035581465‏
996 ‎‡2 NKC|mub20201084364‏
996 ‎‡2 NUKAT|n 2011241004‏
996 ‎‡2 NKC|pna2005262112‏
996 ‎‡2 LC|n 79081862‏
996 ‎‡2 ISNI|0000000084678257‏
996 ‎‡2 LC|n 2012189425‏
996 ‎‡2 ISNI|0000000046727951‏
996 ‎‡2 RERO|A012709632‏
996 ‎‡2 LC|no2017134802‏
996 ‎‡2 BIBSYS|90764915‏
996 ‎‡2 NUKAT|n 2013006108‏
996 ‎‡2 NTA|156185830‏
996 ‎‡2 LC|n 2001127736‏
996 ‎‡2 DNB|135945208‏
996 ‎‡2 LC|nr 89002351‏
996 ‎‡2 ISNI|0000000120245468‏
996 ‎‡2 LIH|LNB:BG_i__p_;=B_y_‏
996 ‎‡2 NUKAT|n 2014080880‏
996 ‎‡2 LC|n 2008165061‏
996 ‎‡2 ISNI|0000000451381958‏
996 ‎‡2 ISNI|0000000435222850‏
996 ‎‡2 LC|no2006012004‏
996 ‎‡2 LC|n 88288093‏
996 ‎‡2 CAOONL|ncf10408414‏
996 ‎‡2 LC|n 86011990‏
996 ‎‡2 RERO|A027359503‏
996 ‎‡2 DNB|138112282‏
996 ‎‡2 ISNI|0000000041338754‏
996 ‎‡2 ISNI|0000000501620284‏
996 ‎‡2 CAOONL|ncf13710260‏
996 ‎‡2 NTA|067969127‏
996 ‎‡2 CAOONL|ncf11226143‏
996 ‎‡2 NTA|167958046‏
996 ‎‡2 LC|nb 99064060‏
996 ‎‡2 J9U|987007393189705171‏
996 ‎‡2 NTA|072544341‏
996 ‎‡2 ISNI|0000000381591158‏
996 ‎‡2 LC|n 2009181420‏
996 ‎‡2 LC|no2001038128‏
996 ‎‡2 J9U|987007342174105171‏
996 ‎‡2 NKC|xx0206542‏
996 ‎‡2 RERO|A012492458‏
996 ‎‡2 LC|n 92022302‏
996 ‎‡2 NKC|uk2007357324‏
996 ‎‡2 PLWABN|9813218094305606‏
996 ‎‡2 LC|nb2004025822‏
996 ‎‡2 DNB|1142030814‏
996 ‎‡2 NLA|000035175139‏
996 ‎‡2 BIBSYS|5082795‏
996 ‎‡2 BIBSYS|5082796‏
996 ‎‡2 NUKAT|n 99008110‏
996 ‎‡2 ISNI|000000007879581X‏
996 ‎‡2 BAV|495_186708‏
996 ‎‡2 ISNI|0000000488552845‏
996 ‎‡2 LC|nr2001007336‏
996 ‎‡2 LC|n 84060297‏
996 ‎‡2 LC|n 95098588‏
996 ‎‡2 LC|no2016015347‏
996 ‎‡2 DNB|1181039002‏
996 ‎‡2 LC|n 2011049927‏
996 ‎‡2 ISNI|0000000029151153‏
996 ‎‡2 DNB|1014041902‏
996 ‎‡2 LC|n 99046422‏
996 ‎‡2 NTA|067573932‏
996 ‎‡2 BIBSYS|4047265‏
996 ‎‡2 RERO|A003350000‏
996 ‎‡2 SUDOC|149224249‏
996 ‎‡2 N6I|vtls000290126‏
996 ‎‡2 ISNI|0000000430918920‏
996 ‎‡2 LC|n 2023007943‏
996 ‎‡2 LC|n 2013004046‏
996 ‎‡2 NUKAT|n 2008092641‏
996 ‎‡2 SUDOC|091025893‏
996 ‎‡2 NUKAT|n 96025528‏
996 ‎‡2 DNB|119036517‏
996 ‎‡2 JPG|500144238‏
996 ‎‡2 ISNI|0000000046141459‏
996 ‎‡2 NTA|125086563‏
996 ‎‡2 ISNI|0000000022867482‏
996 ‎‡2 B2Q|0000101612‏
996 ‎‡2 BIBSYS|90166173‏
996 ‎‡2 PLWABN|9810603405605606‏
996 ‎‡2 NDL|00468001‏
996 ‎‡2 LC|no2019184266‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏